Research programme: recombinant idursulfase - JCR Pharmaceuticals/GlaxoSmithKline

Drug Profile

Research programme: recombinant idursulfase - JCR Pharmaceuticals/GlaxoSmithKline

Alternative Names: GSK-2788723; iduronate-2-sulfatase; JR-032; JR-141; recombinant idursulfase; recombinant-iduronate-2-sulfatase

Latest Information Update: 28 Aug 2012

Price : $50

At a glance

  • Originator JCR Pharmaceuticals
  • Developer GlaxoSmithKline KK; JCR Pharmaceuticals
  • Class Iduronate sulfatases
  • Mechanism of Action Iduronate sulfatase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Mucopolysaccharidosis II

Most Recent Events

  • 28 Aug 2012 This programme is still in active development
  • 10 Sep 2009 Preclinical trials in Mucopolysaccharidosis II in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top